ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response

Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial. - Abstract - Europe PMC

Oral Abstracts - 2020 - International Journal of Rheumatic Diseases - Wiley Online Library

Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study, Arthritis Research & Therapy

Changes from baseline in ASDAS and BASFI over time. Dashed line: all

A and B, Percentages of patients in the golimumab (GLM) and placebo

Frontiers Targeted Therapies in Axial Psoriatic Arthritis

PDF] ASAS40 and ASDAS clinical responses in the ABILITY-1 clinical trial translate to meaningful improvements in physical function, health-related quality of life and work productivity in patients with non-radiographic axial spondyloarthritis

Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies

Disease Control Data, Ankylosing Spondylitis

Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study

Disease Control Data, Ankylosing Spondylitis

Percentages of patients achieving ASDAS LDA (

Disease Control Data, Ankylosing Spondylitis